May 8 (Reuters) - GRI Bio Inc GRI.O:
GRI BIO’S INTERIM BIOMARKER DATA DEMONSTRATE POSITIVE TREND TOWARDS ANTI-FIBROTIC EFFECT OF GRI-0621 IN FIRST TWELVE PATIENTS OF ONGOING PHASE 2A STUDY IN IDIOPATHIC PULMONARY FIBROSIS (“IPF”)
GRI BIO INC - INTERIM DATA EXPECTED Q2 2025, TOPLINE DATA Q3 2025
Source text: ID:nGNX8CcK52
Further company coverage: GRI.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.